Progress in Vascular Disease Treatments: Hype vs. Reality

 

Today we are witnessing unprecedented rapid development and dissemination of new scientific information regarding vascular diseases, and it is becoming increasingly difficult for busy practitioners to keep up with the avalanche of information, according to Dr. Bruce A. Perler.

To help practitioners differentiate the hype from reality, the “Progress in the Medical Treatments of Vascular Disease; Vascular Diseases and Risk Prediction” session on Friday will bring together internationally respected experts in the field. These faculty will present “the latest and most important advances in the perioperative and long-term medical management of our patients in a succinct and easily digestible fashion,” said Dr. Perler of Johns Hopkins University School of Medicine, who will co-moderate the session with Dr. Caron B. Rockman of New York University School of Medicine.

“Vascular surgeons are the only true comprehensive specialists treating circulatory disease who provide the entire spectrum of therapeutic options: endovascular therapy, conventional open surgery, and medical treatment of patients. In the current rapidly evolving health care environment, reimbursement will be increasingly linked to quality outcomes rather than procedural volumes. Achieving the best outcomes of our therapeutic procedures, and providing the optimal overall vascular care for our patients, will be absolutely dependent not only upon proper patient selection and preparation for interventions, but also clearly aligned with providing state of the art perioperative and long-term medical management,” Dr. Perler said.

He added that the information presented in this session will afford the practitioner the latest scientifically proven perioperative and long-term therapy to optimize the patient’s circulatory health.

Further, attendees can take what they learn in this session back to their practice to properly counsel patients about their care – and to answer the questions that patients often bring to the office about these drugs and issues that they hear about in the lay press, he said.

Two critically important talks to be included in the session are: “Which Patients Should Receive Primary Prevention Lipid Lowering Statin Therapy: What Drug and Dose: How Do the HOPE 3 Trial Findings Help,” by Jeffrey S. Berger, MD, associate professor of medicine and surgery, NYU School of Medicine, and “How Do PCSK-9 Inhibitors Work: When and How Should They Currently Be Used: Advantages and Limitations,” by Dr. Natalie A. Marks of the NYU Lutheran Medical Center, he said.

“Hardly a month goes by without yet another article appearing in the lay press about statins. Patients are aware of statins, the associated controversies, and now are hearing about PCSK-9 inhibitors. These talks will inform the vascular surgeon about the key issues with respect to statin therapy and this exciting new alternative,” he said.

Among the nine other informative talks to be presented in the session cover important topics such as ACE inhibitors, angiotensin receptor blockers, the use of cilostazol, and troponin texting.

“Achieving the best results of our vascular surgical procedures requires more than doing the right procedure on the right patient at the right time,” Dr. Perler said. “It also requires managing the patient’s medical and perioperative care compulsively. Keeping abreast of the latest developments, highlighted in this session, will not only optimize your patients’ care, but provide a competitive practice advantage for the contemporary vascular surgeon.”

 

Today we are witnessing unprecedented rapid development and dissemination of new scientific information regarding vascular diseases, and it is becoming increasingly difficult for busy practitioners to keep up with the avalanche of information, according to Dr. Bruce A. Perler.

To help practitioners differentiate the hype from reality, the “Progress in the Medical Treatments of Vascular Disease; Vascular Diseases and Risk Prediction” session on Friday will bring together internationally respected experts in the field. These faculty will present “the latest and most important advances in the perioperative and long-term medical management of our patients in a succinct and easily digestible fashion,” said Dr. Perler of Johns Hopkins University School of Medicine, who will co-moderate the session with Dr. Caron B. Rockman of New York University School of Medicine.

“Vascular surgeons are the only true comprehensive specialists treating circulatory disease who provide the entire spectrum of therapeutic options: endovascular therapy, conventional open surgery, and medical treatment of patients. In the current rapidly evolving health care environment, reimbursement will be increasingly linked to quality outcomes rather than procedural volumes. Achieving the best outcomes of our therapeutic procedures, and providing the optimal overall vascular care for our patients, will be absolutely dependent not only upon proper patient selection and preparation for interventions, but also clearly aligned with providing state of the art perioperative and long-term medical management,” Dr. Perler said.

He added that the information presented in this session will afford the practitioner the latest scientifically proven perioperative and long-term therapy to optimize the patient’s circulatory health.

Further, attendees can take what they learn in this session back to their practice to properly counsel patients about their care – and to answer the questions that patients often bring to the office about these drugs and issues that they hear about in the lay press, he said.

Two critically important talks to be included in the session are: “Which Patients Should Receive Primary Prevention Lipid Lowering Statin Therapy: What Drug and Dose: How Do the HOPE 3 Trial Findings Help,” by Jeffrey S. Berger, MD, associate professor of medicine and surgery, NYU School of Medicine, and “How Do PCSK-9 Inhibitors Work: When and How Should They Currently Be Used: Advantages and Limitations,” by Dr. Natalie A. Marks of the NYU Lutheran Medical Center, he said.

“Hardly a month goes by without yet another article appearing in the lay press about statins. Patients are aware of statins, the associated controversies, and now are hearing about PCSK-9 inhibitors. These talks will inform the vascular surgeon about the key issues with respect to statin therapy and this exciting new alternative,” he said.

Among the nine other informative talks to be presented in the session cover important topics such as ACE inhibitors, angiotensin receptor blockers, the use of cilostazol, and troponin texting.

“Achieving the best results of our vascular surgical procedures requires more than doing the right procedure on the right patient at the right time,” Dr. Perler said. “It also requires managing the patient’s medical and perioperative care compulsively. Keeping abreast of the latest developments, highlighted in this session, will not only optimize your patients’ care, but provide a competitive practice advantage for the contemporary vascular surgeon.”

 

Today we are witnessing unprecedented rapid development and dissemination of new scientific information regarding vascular diseases, and it is becoming increasingly difficult for busy practitioners to keep up with the avalanche of information, according to Dr. Bruce A. Perler.

To help practitioners differentiate the hype from reality, the “Progress in the Medical Treatments of Vascular Disease; Vascular Diseases and Risk Prediction” session on Friday will bring together internationally respected experts in the field. These faculty will present “the latest and most important advances in the perioperative and long-term medical management of our patients in a succinct and easily digestible fashion,” said Dr. Perler of Johns Hopkins University School of Medicine, who will co-moderate the session with Dr. Caron B. Rockman of New York University School of Medicine.

“Vascular surgeons are the only true comprehensive specialists treating circulatory disease who provide the entire spectrum of therapeutic options: endovascular therapy, conventional open surgery, and medical treatment of patients. In the current rapidly evolving health care environment, reimbursement will be increasingly linked to quality outcomes rather than procedural volumes. Achieving the best outcomes of our therapeutic procedures, and providing the optimal overall vascular care for our patients, will be absolutely dependent not only upon proper patient selection and preparation for interventions, but also clearly aligned with providing state of the art perioperative and long-term medical management,” Dr. Perler said.

He added that the information presented in this session will afford the practitioner the latest scientifically proven perioperative and long-term therapy to optimize the patient’s circulatory health.

Further, attendees can take what they learn in this session back to their practice to properly counsel patients about their care – and to answer the questions that patients often bring to the office about these drugs and issues that they hear about in the lay press, he said.

Two critically important talks to be included in the session are: “Which Patients Should Receive Primary Prevention Lipid Lowering Statin Therapy: What Drug and Dose: How Do the HOPE 3 Trial Findings Help,” by Jeffrey S. Berger, MD, associate professor of medicine and surgery, NYU School of Medicine, and “How Do PCSK-9 Inhibitors Work: When and How Should They Currently Be Used: Advantages and Limitations,” by Dr. Natalie A. Marks of the NYU Lutheran Medical Center, he said.

“Hardly a month goes by without yet another article appearing in the lay press about statins. Patients are aware of statins, the associated controversies, and now are hearing about PCSK-9 inhibitors. These talks will inform the vascular surgeon about the key issues with respect to statin therapy and this exciting new alternative,” he said.

Among the nine other informative talks to be presented in the session cover important topics such as ACE inhibitors, angiotensin receptor blockers, the use of cilostazol, and troponin texting.

“Achieving the best results of our vascular surgical procedures requires more than doing the right procedure on the right patient at the right time,” Dr. Perler said. “It also requires managing the patient’s medical and perioperative care compulsively. Keeping abreast of the latest developments, highlighted in this session, will not only optimize your patients’ care, but provide a competitive practice advantage for the contemporary vascular surgeon.”